Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexofenadine Hydrochloride in STEMI Patients
NCT06548204Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fexofenadine in ST-segment elevation myocardial infarction (STEMI), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Jan 2025; status: recruiting.
02
Drugs
fexofenadine
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06548204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548204.